Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
A Phase 1, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).
研究概览
地位
条件
详细说明
This study is a double-blinded, randomised, active controlled, Phase 1 clinical study, to determine the safety, tolerability, and reactogenicity of Serum Institute of India Pvt Ltd (SIIPL) rPV vaccine in comparison to the commercially available inactivated poliovirus vaccine (IPOL®, Sanofi) in up to 36 healthy adults aged between 18 and 60 years. This study will be conducted at a single study site in Australia.
Participants will be randomised in a 2:1 ratio, to receive either investigational vaccine (rPV) or comparator vaccine (IPOL), respectively. The study vaccine will be administered as a single intramuscular (IM) injection into the deltoid muscle of the non-dominant upper arm. The participants will be followed for 30 days post vaccination.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Dr Hitt Sharma, MBBS MBA
- 电话号码:+91-9822418354
- 邮箱:drhjs@seruminstitute.com
研究联系人备份
- 姓名:Dr Sameer Parekh, MBA
- 电话号码:+91-9226722745
- 邮箱:sameer.parekh@seruminstitute.com
学习地点
-
-
Victoria
-
East Melbourne、Victoria、澳大利亚、3002
- 招聘中
- Doherty Clinical Trials Limited
-
接触:
- Nicola Byrne
- 电话号码:+61 03 9970 4200
- 邮箱:nbyrne@dohertyclinicaltrials.com
-
首席研究员:
- Dr Gail Cross, MBBS FRACP PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Healthy Volunteers aged between 18 to 60 years inclusive.
- Good physical and mental health based on medical history, physical examination, clinical laboratory,electrocardiogram (ECG), and vital signs, as judged by the Investigator.
- Participants must refrain from strenuous exercise within 96 hours (4 days) prior to Screening, Day 1, Day 8,and Day 30..
- Willing and able to comply with restrictions of nicotine (i.e., tobacco and nicotine products) usethroughout the study is not permitted from within 48 hours (2 days) prior to Screening, from Day 1 until Day8, and within 48 hours (2 days) prior to the end of study visit.
- Participants must agree to use highly effective contraception from Day 1 until 90 days after the last studyvisit.
Key Exclusion Criteria:
- History of Polio
- Any vaccination received 30 days before Screening and Day 30
- Pregnant or lactating females
- BMI >35.0kg/m2
- History of alcohol abuse or drug addiction
- Have received any polio vaccines within 6 months prior to screening.
- History of major surgeries
- History of receipt of a blood transfusion, other blood products, or immunoglobulins in 3 months prior tostudy vaccination
- any confirmed or suspected congenital or acquired immunosuppressive or immunodeficient condition.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Recombinant Poliomyelitis Vaccine (rPV)
|
Recombinant Poliomyelitis Vaccine (VLP) is manufactured by Serum Institute of India Pvt. Ltd. |
|
有源比较器:Inactivated Poliomyelitis Vaccine (IPOL)
|
IPOL (inactivated poliovirus vaccine) is a marketed Sanofi |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The incidence, severity and relationship of solicited adverse events (AEs) during 7-day and unsolicited AEs during 30-day follow-up period after rPV and IPOL vaccination
大体时间:30 days
|
30 days
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Percentage of participants achieving seroprotection/seroconversion for poliovirus Types 1, 2 and 3, on Day 30.
大体时间:30 days
|
30 days
|
合作者和调查者
调查人员
- 研究主任:Dr Hitt Sharma, MBBS MBA、Serum Institute of India Pvt. Ltd.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- SII-rPV-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Summary results
IPD 共享时间框架
12 months after completion of the study
IPD 共享访问标准
Researchers who provide a methodologically sound proposal may be provided the access afterSponsor permission and if signed data-access agreements are in place.
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.